ClinicalTrials.Veeva

Menu

Graz Study on the Risk of Atrial Fibrillation (GRAF)

M

Medical University of Graz

Status and phase

Unknown
Phase 4

Conditions

Hypertension
Atrial Fibrillation
Vascular Disease
Diabetes
Chronic Heart Failure

Treatments

Device: Medtronic Reveal XT implantable loop recorder

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01461434
GRAF-01-SCCT

Details and patient eligibility

About

Atrial fibrillation (AF) is the most common clinical arrhythmia. AF is associated with increased risk for stroke due to blood clots formed in the fibrillating atria. Some patient characteristics increase the likelyhood of AF and at the same time the risk of stroke when AF has developed. To reduce the risk of stroke, anticoagulation therapy is recommended in patients with AF and risk factors (such as high blood pressure, diabetes, vessel disease). However, occasional (paroxysmal) AF may occur without symptoms and remain undetected, leaving patients at risk.

Aim of the prospective randomized study is to compare two management strategies for patients at increased risk for AF but without a known history of AF. Patients are seen regularly (monthly, then quarterly) for follow-up (incl. ECG recording and blood sample). One group of patients additionally receives a subcutaneous implantation of a loop recorder for continuous rhythm monitoring, while the control group remains on standard follow-up. Observation period is one year (optional extension for 3 years). The time to first diagnosis of AF is compared between groups, blood samples are analyzed for potential biomarkers of AF.

Enrollment

82 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • CHA2DS2-VASc risk score >= 4*
  • 18 years or older

Exclusion criteria

  • known history of atrial fibrillation
  • implanted rhythm device
  • pre-existing indication for oral anticoagulation

(*)CHA2DS2-VASc: C - chronic heart failure (1 point); H - hypertension (1 point); A - age >= 75 years (2 points); D - diabetes (1 point); S - stroke (2 points); V - vascular disease (1 point); A - age >=65 and < 75 years (1 point); Sc - sex category (female) (1 point) ;

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

82 participants in 2 patient groups

loop recorder
Experimental group
Description:
patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
Treatment:
Device: Medtronic Reveal XT implantable loop recorder
regular follow-up
No Intervention group
Description:
patients will receive regular follow-ups with standard ECG

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems